Platelets, CBC.
Reading File
Asking for Preferences
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Finding Sources
Reading File
Reading File
Reading File
Finding Sources
Reading File
Reading File
I now have comprehensive information across all requested topics. Let me compile the full overview.
Platelets and the Complete Blood Count (CBC) - Full Overview
1. What Are Platelets?
Platelets (thrombocytes) are thin, anucleate disks, 2-4 µm in diameter and 5-7 fL in volume (in citrated blood). They are not cells in the traditional sense but rather fragments shed from megakaryocytes. Their normal lifespan is ~10 days, and they spend their entire existence in the circulating blood.
Henry's Clinical Diagnosis and Management by Laboratory Methods
2. Platelet Production (Thrombopoiesis)
Platelets are produced from megakaryocytes in the bone marrow - giant polyploid cells (50-100 µm in diameter) that undergo endomitosis (repeated DNA replication without cell division), reaching up to 16N ploidy. This DNA amplification allows a single megakaryocyte to generate up to 5,000 platelets.
- Megakaryocytes extend long cytoplasmic processes (proplatelet processes) into vascular sinusoids; platelets bud off from these extensions
- Microtubules drive proplatelet elongation and transport organelles and granules into nascent platelets
- Platelets carry functional mRNA and microRNA from the parent megakaryocyte and retain the molecular machinery to translate mRNA into protein
Regulation:
- Thrombopoietin (TPO) is the primary regulator, produced constitutively by the liver. Plasma TPO levels are regulated inversely by the total mass of platelets and megakaryocyte progenitors - more platelets = more TPO clearance = lower plasma TPO
- Cytokines that amplify megakaryocyte production: IL-1, IL-3, IL-6, IL-11, stem cell factor (Kit ligand), GM-CSF
- An elevated mean platelet volume (MPV) on CBC indicates increased megakaryocyte production, typically compensating for accelerated platelet destruction (e.g., ITP, Bernard-Soulier syndrome)
Firestein & Kelley's Textbook of Rheumatology; Harrison's Principles of Internal Medicine 22E
3. Platelet Physiology - Hemostasis and Coagulation
Following vascular injury, platelets undergo a coordinated sequence:
Step 1 - Adhesion
- Intact endothelium releases prostacyclin, nitric oxide, thrombomodulin, and ADPase (CD39) to keep platelets quiescent
- Injury triggers vasoconstriction and exposes subendothelial collagen and von Willebrand factor (vWF)
- Under high shear stress, the GPIb-IX-V complex (~25,000 copies/platelet) binds vWF bound to the wound site, mediating transient tethering
- GPVI (collagen receptor) and integrin α2β1 stabilize the association
Step 2 - Activation and Shape Change
- Platelets change from discoid to spherical
- Agonists (ADP, collagen, thrombin, thromboxane A2 [TXA2], epinephrine, PAF) bind specific platelet surface receptors
- Key intracellular signaling:
- ADP acts via P2Y1 (raises cytoplasmic Ca²⁺), P2Y12 (lowers cAMP; target of clopidogrel/prasugrel), and P2X1 (ion channel)
- Thrombin acts via PAR1 and PAR4 receptors
- Downstream: phospholipase C generates DAG and IP3; IP3 mobilizes intracellular Ca²⁺; phospholipase A2 converts arachidonic acid to TXA2 (a potent platelet activator and vasoconstrictor)
- G-proteins (rap1A, rap1B) mediate receptor-enzyme coupling
Step 3 - Aggregation
- Inside-out signaling activates GPIIb-IIIa (integrin αIIbβ3, ~80,000 copies/platelet)
- Activated GPIIb-IIIa binds fibrinogen, cross-linking platelets together (platelet aggregation)
- GPIIb-IIIa also binds fibronectin, vWF, thrombospondin, and vitronectin
Step 4 - Secretion (Release Reaction)
- Dense granules: release ADP and serotonin → recruit additional platelets
- Alpha granules: release fibrinogen, vWF, P-selectin, platelet factor 4, PDGF
- Lysosomal granules: hydrolytic enzymes
- Granule fusion is mediated by SNARE complexes
Step 5 - Platelet Coagulant Activity
- Platelet membrane phospholipids provide the surface for key coagulation cascade reactions (prothrombinase complex: Xa/Va; tenase complex: IXa/VIIIa), markedly accelerating thrombin generation
Key inherited defects:
- Absence of GPIb-IX-V → Bernard-Soulier syndrome (failure to adhere)
- Absence of GPIIb-IIIa → Glanzmann's thrombasthenia (failure to aggregate)
- ADAMTS-13 mutation or autoantibody depletion → TTP (uncontrolled vWF-mediated platelet clumping)
Henry's Clinical Diagnosis; Firestein & Kelley's Rheumatology
4. CBC - Components and Normal Values
A complete blood count (CBC) is the most commonly ordered hematology panel. Modern analyzers use flow cytometry, light detection, and electrical impedance to count ~10,000 cells per category.
| Component | What It Measures | Key Clinical Interpretation |
|---|---|---|
| WBC (Leukocyte count) | Total white cell count | Leukocytosis (>11 × 10⁹/L): infection, inflammation, stress, leukemia; Leukopenia: chemotherapy, autoimmune, HIV |
| Differential | Neutrophils, eosinophils, basophils, lymphocytes, monocytes, bands | Each subset reflects specific immune processes |
| RBC count | Total red cell count | ↑ polycythemia (vera, high altitude); ↓ anemia |
| Hemoglobin (Hgb) | O2-carrying protein in RBCs | Men: 13.5-17.5 g/dL; Women: 12-15.5 g/dL |
| Hematocrit (HCT/PCV) | % volume occupied by RBCs | Mirrors Hgb (rule: HCT ≈ 3× Hgb) |
| MCV | Mean corpuscular volume (RBC size) | Low = microcytic (iron deficiency); High = macrocytic (B12/folate deficiency) |
| MCH | Hgb content per RBC | Reflects MCV trends |
| MCHC | Hgb concentration per RBC | Low = hypochromic; high = hereditary spherocytosis |
| RDW | Variation in RBC size | ↑ = anisocytosis; helps differentiate anemias |
| Platelet (Thrombocyte) count | Number of platelets | Normal: 150,000-400,000/µL (150-400 × 10⁹/L) |
| MPV | Mean platelet volume | Larger platelets = younger, more active; ↑ MPV suggests peripheral destruction with compensatory increased production |
Histology: A Text and Atlas (Eroschenko); Henry's Clinical Diagnosis
5. Platelet Count Interpretation
Normal Range
150,000-400,000/µL (150-400 × 10⁹/L)
Thrombocytopenia (count < 150 × 10⁹/L)
The four major mechanisms:
| Mechanism | Examples |
|---|---|
| Decreased production | Aplastic anemia, leukemia, myelodysplasia, alcohol, HIV infection, chemotherapy, CMV, EBV, radiation |
| Increased destruction (immune) | ITP (autoantibody to GPIIb/IIIa or GPIb/IX), drug-induced (quinine, sulfonamides, β-lactams, vancomycin, gold), alloimmune (neonatal), SLE, HIV |
| Increased destruction (non-immune) | DIC, TTP, HUS, HIT, preeclampsia/eclampsia, sepsis, prosthetic heart valves, cardiopulmonary bypass |
| Sequestration | Splenomegaly (normally spleen holds 30-35% of platelets; enlarged spleen can trap up to 80-90%) |
| Dilution | Massive transfusion |
Practical note: Any automated thrombocytopenia count <60 × 10⁹/L must be confirmed by blood smear before altering management. Spurious low counts can result from:
- EDTA-induced platelet aggregation (clumping)
- Platelet satellitism (platelets surrounding neutrophils in EDTA samples)
- Fibrin strands activating coagulation in the tube
"A platelet transfusion should never be given for an unexpected thrombocytopenia without microscopic confirmation of the count." - Goldman-Cecil Medicine
Immune Thrombocytopenic Purpura (ITP)
- Autoantibodies (usually IgG, directed at GPIIb/IIIa or GPIb/IX) opsonize platelets
- Opsonized platelets removed by IgG Fc receptors on phagocytes, mainly in the spleen
- Autoantibodies demonstrable in ~80% of patients
- Splenectomy markedly improves counts (removes both the destruction site and a major autoantibody source)
- Antibodies may also bind megakaryocytes, reducing platelet production
Robbins, Cotran & Kumar; Goldman-Cecil Medicine
Thrombocytosis (count > 400 × 10⁹/L)
| Type | Causes |
|---|---|
| Reactive (secondary) | Iron deficiency, infection, inflammation, post-splenectomy, surgery, tissue damage, malignancy |
| Primary (clonal) | Essential thrombocythemia (ET), polycythemia vera (PV), primary myelofibrosis (PMF) |
Essential Thrombocythemia (ET):
- Often discovered incidentally on routine blood count
- Blood smear shows markedly elevated platelets, some very large
- May cause hemorrhagic (easy bruising) or thrombotic/microvascular events (erythromelalgia, ocular migraine, TIA)
- Paradoxically: MPL (TPO receptor) expression is impaired, so plasma TPO is elevated despite elevated platelet counts
- Spurious hyperkalemia and false arterial O2 readings can occur from platelet degranulation in the test tube
Harrison's Principles of Internal Medicine 22E
6. Key Peripheral Smear Findings Related to Platelets
| Finding | Significance |
|---|---|
| Giant platelets | Inherited thrombocytopenias (Bernard-Soulier), ET, MYH9 disorders |
| Schistocytes + thrombocytopenia | TTP, HUS, DIC, HELLP syndrome |
| Platelet clumps | EDTA-induced pseudothrombocytopenia |
| Platelet satellitism | EDTA artifact, can falsely lower automated count |
| Hypersegmented neutrophils | B12/folate deficiency (may coexist with thrombocytopenia) |
7. Summary of Antiplatelet Drug Targets
| Drug | Target | Mechanism |
|---|---|---|
| Aspirin | Cyclooxygenase (COX-1) | Blocks TXA2 synthesis irreversibly |
| Clopidogrel, Prasugrel | P2Y12 receptor | Block ADP-mediated platelet activation |
| Abciximab, Eptifibatide, Tirofiban | GPIIb-IIIa | Block fibrinogen binding, prevent aggregation |
Sources:
- Henry's Clinical Diagnosis and Management by Laboratory Methods - Platelet counts, morphology, role in hemostasis
- Firestein & Kelley's Textbook of Rheumatology - Platelet production, hemostasis signaling
- Goldman-Cecil Medicine - Thrombocytopenia causes, assessment, blood smear approach
- Robbins, Cotran & Kumar Pathologic Basis of Disease - ITP pathogenesis
- Harrison's Principles of Internal Medicine 22E - Thrombopoietin regulation, essential thrombocythemia
- Histology: A Text and Atlas (Eroschenko) - CBC components and reference values
This is a shared conversation. Sign in to Orris to start your own chat.